Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).
David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.
James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia when initial therapy is given in academic hospitals vs nonacademic hospitals (Abstract 268).
Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses in French a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577).
